Publications

Read Now

19 Sep 2023
HBS Case

How Will the Tech Titans Behind ChatGPT, Bard, and LLaMA Make Money?

on. It will transform the world, but the money isn't made on the thing that enabled the transformation. “The issue is, we normally think of intellectual property as being copyrighted or not copyrighted.”... View Details

Keywords: by Ben Rand; Technology; Information Technology

01 Dec 2015
HBS Seminar

Nicola Lacetera, University of Toronto

Web

Curriculum - MBA

with a focus on prediction, reproducibility, and validation. Spring Term HBS MBA Required Curriculum Harvard Business School Fall and Spring of Year 1 is spent at HBS completing the MBA Required Curriculum (RC). Life Science, Ethics, and View Details

Richard G. Hamermesh

Richard Hamermesh was the MBA Class of 1961 Professor of Management Practice at the Harvard Business School. While at HBS Richard served as co-chair of the HBS Healthcare... View Details

Keywords: health care

10 Jan 2013
Working Paper Summaries

The Novelty Paradox & Bias for Normal Science: Evidence from Randomized Medical Grant Proposal Evaluations

Keywords: by Kevin J. Boudreau, Eva C. Guinan, Karim R. Lakhani & Christoph Riedl; Health

February 2009
Article

GHG Trading Framework for the U.S. Biofuels Sector

By: Subbu Kumarappan and Satish V. Joshi

Substitution of petroleum fuels with biofuels such as ethanol and biodiesel has been shown to reduce greenhouse gas (GHG) emissions. These GHG reductions can be traded in the emerging carbon markets, and methodologies for quantifying and trading are still being... View Details

Keywords: Climate Change; Environmental Sustainability; Energy Sources; Energy Industry; United States

Read Now

Professor Louis T. Wells is the Herbert F. Johnson Professor of International Management at the Harvard Business School. He has served as consultant to governments of a number of developing countries, as well as to international organizations and private firms. His... View Details

Keywords: mining; telecommunications; utilities

December 2005 (Revised August 2006)
Case

Amgen Inc.'s Epogen--Commercializing the First Biotech Blockbuster Drug

By: Felix Oberholzer-Gee and Dennis A. Yao

Amgen Inc.'s Epogen was the first biotech blockbuster drug. Epogen helped prevent anemia, a condition that leads to severe fatigue, increased risk of cardiovascular disease, and even death. At the time, the market for Epogen, which included dialysis patients and... View Details

Keywords: Health Care and Treatment; Strategic Planning; Competition; Patents; Innovation and Invention; Pharmaceutical Industry; Biotechnology Industry; United States

Research Summary

Competing on a Common Platform

Why have over 100 firms joined the Eclipse Foundation to collectively produce an open source platform and tools for software application development? What are they trying to accomplish? This research analyzes IBMs divestment of the Eclipse Java Integrated Development... View Details

July 2019 (Revised October 2022)
Case

Jai Vakeel Foundation: Addressing Disability

By: V. Kasturi Rangan and Kairavi Dey

Jai Vakeel, a nonprofit organization in India, serves individuals with Intellectual Disability (ID), those with an IQ below 70. The organization was founded by the parents of a child with Down Syndrome, and they (and their next generation) steadily built the... View Details

Keywords: Social Enterprise; Nonprofit Organizations; Transition; Growth and Development Strategy; Organizational Change and Adaptation; Family Business; Health Care and Treatment; India

Web

Browse All Articles, Research, & Case Studies - HBS Working Knowledge

John Macomber argues that private investors could play a pivotal role in developing adaptation projects that provide strong returns. 06 Nov 2024 Managing the Future of Work Guest Episode: Joseph Fuller on The Gartner Talent Angle Bill... View Details

Web

MD/MBA Harvard Medical School - MBA

MD/MBA MD/MBA A joint degree with Harvard Medical School. In recognition of the critical need for leaders educated in the intellectual disciplines and practices of medicine and management, Harvard Medical School (HMS) and Harvard Business... View Details

August 2024
Case

Oculii

By: Andy Wu and Lucas Defilippo

It was a bright June day in 2016. Steven Hong, co-founder and COO of Oculii had just signed a letter of intent agreeing to a 51% stake acquisition by Nexteer Automotive, a global steering and driveline supplier company that developed advanced driver assistance systems... View Details

Keywords: Automotive; Supply Chain; Autonomous Vehicles; Wireless Communications

25 Jul 2005
Research & Ideas

Fool vs. Jerk: Whom Would You Hire?

jerk. Things got a lot more interesting, though, when people faced the choice between competent jerks and lovable fools. Ask managers about this choice—and we've asked many of them, both as part of our research and in executive education... View Details

Keywords: by Tiziana Casciaro & Miguel Sousa Lobo

Josh Lerner

Josh Lerner graduated from Yale College with a special divisional major. He worked for several years on issues concerning technological innovation and public policy at the Brookings Institution, for a public-private task force in Chicago, and on... View Details

Keywords: biotechnology; high technology; venture capital industry

Web

Employment | Harvard Business School

whose mission-driven work provides real value and impact. Faculty Positions Join a culturally diverse full-time intellectual community that draws on their research to educate leaders who make a difference in the world and help shape the... View Details

September 2020
Case

Minerva 2004: Discovery

By: John R. Wells and Benjamin Weinstock

After nearly five years in operation, Doctor Cynthia Bamdad, founder and CEO of Minerva Biotechnologies Corporation (Minerva), was reflecting on the company’s next steps. In a few short years, she and her small team had managed to develop a nanoparticle process for... View Details

Keywords: Entrepreneurship; Financing and Loans; Strategy; Decision Choices and Conditions; Biotechnology Industry